Building confidence in the COVID-19 vaccine through education
By Megan Van Etten | March 22, 2021
Throughout the COVID-19 vaccine research and development process, the biopharmaceutical industry has worked to uphold the highest standards of research, clinical testing and manufacturing.
Read More
ICYMI: Bipartisan lawmakers urge new administration to oppose changes to six protected classes policy
By Tom Wilbur | March 11, 2021
On January 19, 2021 – the last full day of the Trump administration – CMS released a Part D Payment Modernization Model Request for Applications (RFA) for calendar year 2022. This model would...
Read More
Getting the 340B program back on track in 2021
By Nicole Longo | March 10, 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have...
Read More
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
By Andrew Powaleny | March 8, 2021
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have made unprecedented progress
Read More
Intellectual property is the key to vaccine development, manufacturing and technology sharing
By Megan Van Etten | March 5, 2021
Earlier today, 31 PhRMA board members signed a letter to President Joe Biden applauding the Administration’s accelerating COVID-19 vaccine rollout, but also warning against efforts to undermine...
Read More
Key takeaways: PhRMA comments to USPTO on how to make the innovation ecosystem more diverse and inclusive
By Abigail Lore | March 5, 2021
Last week, PhRMA submitted comments to the United States Patent and Trademark Office (USPTO) in response to a request for comments on the National Strategy for Expanding American Innovation....
Read More
How industry collaboration and partnerships are supporting COVID-19 vaccine manufacturing
By Richard Moscicki, M.D. | March 4, 2021
Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 vaccine manufacturing. Companies are working to source needed raw materials and other...
Read More
Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter
By Katie Koziara | March 2, 2021
A new study published in Health Affairs finds that for nearly 40% of commercially insured patients, half of their annual out-of-pocket expenses for medical treatments come from just one hospital,...
Read More
Coming together to fight COVID-19: A conversation with Paul Perreault, CEO and Managing Director of CSL
By Stephen J. Ubl | February 24, 2021
This year, our industry has been working around the clock to combat the COVID-19 virus, including developing effective therapeutics to treat COVID-19 and vaccines to prevent future infections.
Read More
ICYMI: Report provides actionable recommendations to strengthen America’s preparedness and future health crises response
By Jocelyn Ulrich | February 22, 2021
As America’s biopharmaceutical researchers continue working around the clock to fight COVID-19, leaders in the health care ecosystem have come together to provide recommendations to strengthen...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
